Building a pioneering team discovering therapeutics from RNA epigenetics Building a pioneering team discovering therapeutics from RNA epigenetics Building a pioneering team discovering therapeutics from RNA epigenetics Building a pioneering team discovering therapeutics from RNA epigenetics

Building a pioneering team discovering
therapeutics from RNA epigenetics

STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.

For further information about STORM Therapeutics, read more about us or complete our enquiry form.

STORM Therapeutics exemplifies the quality of companies with innovative ideas and great commercial potential that continue to spin out of the University of Cambridge.

Robert Tansley, Cambridge Innovation Capital

We are delighted to be working with the founders and co-investors to make STORM Therapeutics a leader in therapeutic modulation of RNA modifying enzymes.

Rob Woodman, Touchstone Innovations

The work that our research groups are undertaking on non-coding RNA and the enzymes that modify this RNA is giving us incredibly interesting insights into how gene expression can be modified at a cellular level.

Professor Eric Miska, Founder, STORM Therapeutics

The funding and support that STORM Therapeutics has received from its investors will allow the development of these insights into a new class of therapeutics ready to be taken into clinical trials.

Professor Tony Kouzarides, Founder, STORM Therapeutics

STORM Therapeutics is a classic example of our model – helping world-leading scientists to turn their outstanding research into exciting early-stage companies by providing long-term funding and building great syndicates of like-minded co-investors.

Rob Woodman, Touchstone Innovations

STORM Therapeutics’ insights into epigenetics provide the potential to open up a range of therapeutic targets to treat cancer.

Robert Tansley, Cambridge Innovation Capital

Investing in breakthrough science

Investing in breakthrough science

Significant investment with a long-term perspective supports our drive to create novel therapeutics that will benefit patients

Find out more

Latest news

Latest news

Keep up to date with all the latest news and events at STORM Therapeutics

Find out more